Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714590 | 0.90 | HSD17B10 (0.71) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL12115502 | 0.75 | ALDH1A1 (0.72) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL7933617 | 0.75 | ALDH1A1 (0.72) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL17988255 | 0.74 | ALDH1A1 (0.68) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL11344627 | 0.73 | ALDH1A1 (1.00) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL26424875 | 0.71 | HPGD (0.66) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL8288716 | 0.71 | ALDH1A1 (0.98) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL8288695 | 0.71 | ALDH1A1 (0.83) | HSD17B10MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL5807478 | 0.70 | ALDH1A1 (0.68) | HSD17B10MAPTALDH1A1TSHRHPGD | |
| SCHEMBL5807480 | 0.70 | ALDH1A1 (0.68) | HSD17B10MAPTALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033363-A1 | ALC1 Inhibitors and Synergy with PARPi | EISBACH BIO GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| CN-117120448-A | ALC1 inhibitors and synergy with PARPi | 艾斯巴赫生物有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4255910-A1 | ALC1 INHIBITORS AND SYNERGY WITH PARPI | Eisbach Bio GmbH (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022117782-A1 | ALC1 INHIBITORS AND SYNERGY WITH PARPI | EISBACH BIO GMBH (DE) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033363-A1 | ALC1 Inhibitors and Synergy with PARPi | PARP11, PARP1, BRCA1 | HSD17B10 1119/4885MAPT 3260/4885ALDH1A1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.